Company / Free Cash Flow
Xilio Therapeutics, Inc. Free Cash Flow History
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$18.4M
FY2025
5-year range
-$69.1M / -$18.4M
FY2024-FY2025
Trend
+73.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
-$18M in FY2025.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow increased 73.4% year-over-year.
Company context
Key Data Points
- Altman Z-Score -0.71 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$18.4M | +73.4% |
| FY2024 | -$69.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026